Ask AI
Treat to Target in CD
Interactive Case Challenge 1: Treat-to-Target in Crohn’s Disease 

Released: March 17, 2025

Activity

Progress
1
Course Completed

Case History and Presentation


After 8 weeks of weekly adalimumab, Ms Lewis reports symptomatic improvement but still experiences 1-2 loose stools daily and mild abdominal discomfort. Additional lab results showed the following: 



  • CRP: 8 mg/L  

  • Fecal calprotectin: 400 μg/g  

  • Trough adalimumab level: 12 mcg/mL with no neutralizing antibodies 

What would be the most appropriate next step in management for this patient?